96 Tests PN: B114557

Components:

45x Ab-conjugated beads (S4P5 - Human IGFBP-1 Ab-bead). PN: B114557A. One vial containing 100 µL of anti-Human IGFBP-1 conjugated to AimPlex Bead S4P5.

25x Biotin-detection Ab (Human IGFBP-1 Biotin-dAb). PN: B114557B. One vial containing 100 µL of biotinylated anti-Human IGFBP-1.

Lyophilized Standard Mix-Human Group 6, Panel B, 12-Plex. PN: HG62013. One vial containing lyophilized recombinant Eotaxin-2, IGFBP-1, IGFBP-7, MCP-4, MDC, MIP-1δ, MIP-3α, MIP-3β, IL-6Rα, IL-1RII, Gp130, and TNFRII. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human IGFBP-1. Can be multiplexed with other analytes in Human Group 6.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 6: Negligible

  • Sample volume: 15 µL/test

Description:

Insulin-like growth factor-binding protein 1 (IGFBP-1) also known as placental protein 12 (PP12) is a member of the Insulin-like growth factor-binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a type-I thyroglobulin domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. Diseases associated with IGFBP-1 include mild pre-eclampsia and uterine disease.

References:

  1. Brinkman A, Groffen C, Kortleve DJ, Geurts van Kessel A, Drop SL (Jan 1989). "Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)". EMBO J 7 (8): 2417–23. PMC 457109. PMID 2461294.

  2. "Site-specific IGFBP-1 hyper-phosphorylation in fetal growth restriction: clinical and functional relevance. (PMID: 20143870) Abu Shehab M. … Gupta M.B.(J. Proteome Res. 2010)

  3. Dietary predictors of the insulin-like growth factor system in adolescent females: results from the Dietary Intervention Study in Children (DISC). (PMID: 20089725) Kerver J.M. … Velie E.M. (Am. J. Clin. Nutr. 2010)

.